Kezar Life Sciences Inc
(NQ:
KZR
)
7.370
-0.040 (-0.54%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kezar Life Sciences Inc
< Previous
1
2
3
4
5
6
7
Next >
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
March 14, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 08, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
March 02, 2024
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global...
Via
Talk Markets
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
Analyst Expectations for Kezar Life Sciences's Future
November 27, 2023
Via
Benzinga
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
February 26, 2024
From
Kezar Life Sciences, Inc.
Via
Business Wire
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
February 25, 2024
When you want to light your afterburners, these ideas will do the trick.
Via
InvestorPlace
3 Penny Stocks Poised for an Unbelievable 1,000% Jump
February 02, 2024
Discover penny stocks with the potential for a 1,000% leap: strategic growth, debt-free stability and pharmaceutical innovation await.
Via
InvestorPlace
As Oversupply Deflates Lithium Bubble, IPO Market Keeps In High Spirits
January 08, 2024
Lithium market facing persistent turmoil as spot prices decline for more than a year. But asset management firm Janus Henderson sees a silver lining.
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Bull Run Bonanza: Top 3 Penny Stocks Primed for Explosive Growth
December 18, 2023
Are you looking for the next bull run bonanza? Here are the top three penny stocks primed for explosive growth.
Via
InvestorPlace
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 03, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
October 23, 2023
Via
ACCESSWIRE
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 09, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
October 03, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
September 23, 2023
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...
Via
Talk Markets
Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
September 21, 2023
Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to...
Via
Benzinga
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
September 20, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
August 31, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 22, 2023
Via
Benzinga
Top 5 Health Care Stocks That Could Blast Off This Month
August 21, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
August 11, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2023
August 11, 2023
Via
Benzinga
Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
August 11, 2023
Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 04, 2023
From
Kezar Life Sciences, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
July 27, 2023
During Thursday, 56 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.